Moderna Pauses mRNA RSV Vaccine Trial For Children

Health & LifestyleNewsPublisher's Picks
503

Listen to article (english)

Translate to Spanish or other 102 languages!

In recent clinical trials, two experimental RSV vaccines for babies may not only have failed to protect them, but actually made some of them sicker when they got RSV or another respiratory virus. Image for illustration purposes
In recent clinical trials, two experimental RSV vaccines for babies may not only have failed to protect them, but actually made some of them sicker when they got RSV or another respiratory virus. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Jon Cohen / Science.org

Recently approved adult vaccines against respiratory syncytial virus (RSV) are already saving lives. But prospects have dimmed for some infant vaccines against the virus, which each year kills up to 100,000 children under age 5 around the world and is the leading cause of infant hospitalizations in the United States. In recent clinical trials, two experimental RSV vaccines for babies may not only have failed to protect them, but actually made some of them sicker when they got RSV or another respiratory virus. 

Follow the link below for the full story:

- Advertisement -

https://www.science.org/content/article/safety-signal-moderna-s-rsv-vaccine-studies-halts-trials-other-vaccines-childhood

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Stay-At-Home Mom Turns Her Life Around At STC 
Next article
Help Loved Ones Seek Support, Medical Help Early for Holiday Anxiety, Depression

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -